Transfusion Medicine Reviews
Volume 24, Issue 1 , Pages 22-32 , January 2010

Extending the Horizon for Cell-Based Immunotherapy by Understanding the Mechanisms of Action of Photopheresis

References 

  1. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:7–12
  2. Marshall SR. Technology insight: ECP for the treatment of GvHD—Can we offer selective immune control without generalized immunosuppression?. Nat Clin Pract Oncol. 2006;3:302–314
  3. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood. 2003;102:1217–1223
  4. Greinix HT, Sociė G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265–273
  5. Abreu MT, Von Tirpitz C, Hardi R, et al. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: Results of an open-label pilot study. Inflamm Bowel Dis. 2009;15:829–836
  6. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): An update. Blood Rev. 2007;21:327–348
  7. Silvis R, Steup WH, Brand A, et al. Protective effect of blood transfusions on postoperative recurrence of Crohn's disease in parous women. Transfusion. 1994;34:242–247
  8. Albert ML. Death-defying immunity: Do apoptotic cells influence antigen processing and presentation?. Nat Rev Immunol. 2004;4:223–231
  9. Scheller C, Knöferle J, Ullrich A, et al. Caspase inhibition in apoptotic T cells triggers necrotic cell death depending on the cell type and the proapoptotic stimulus. J Cell Biochem. 2005;97:1350–1361
  10. Gavathiotis E, Suzuki M, Davis ML, et al. BAX activation is initiated at a novel interaction site. Nature. 2008;455:1076–1081
  11. Griffith TS, Kazama H, VanOosten RL, et al. Apoptotic cells induce tolerance by generating helpless CD8+ T cells that produce TRAIL. J Immunol. 2007;178:2679–2687
  12. Kaye J. CD160 and BTLA: LIGHTs out for CD4+ T cells. Nat Immunol. 2008;9:122–123
  13. Hettmer S, Malott C, Woods W, et al. Biological stratification of human neuroblastoma by complex “B” pathway ganglioside expression. Cancer Res. 2003;63:7270–7276
  14. Caldwell S, Heitger A, Shen W, et al. Mechanisms of ganglioside inhibition of APC function. J Immunol. 2003;171:1676–1683
  15. McKallip R, Li R, Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol. 1999;163:3718–3726
  16. David R. Regulatory T cells: Suppression dissected. Nat Rev Immunol. 2009;9:150–151
  17. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: Mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907–1916
  18. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. 2002;8:1024–1032
  19. Bell E. Tolerance: Key role for DCs in preventing autoimmunity. Nat Rev Immunol. 2009;9:224–225
  20. Van Rhijn I, Young DC, De Jong A, et al. CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. J Exp Med. 2009;206:1409–1422
  21. Chen X, Wang X, Keaton JM, et al. Distinct endosomal trafficking requirements for presentation of autoantigens and exogenous lipids by human CD1d molecules. J Immunol. 2007;178:6181–6190
  22. Moody DB, Zajonc DM, Wilson IA. Anatomy of CD1-lipid antigen complexes. Nat Rev Immunol. 2005;5:387–399
  23. Silva MT, do Vale A, dos Santos NM. Secondary necrosis in multicellular animals: An outcome of apoptosis with pathogenic implications. Apoptosis. 2008;113:463–482
  24. Ohnmacht C, Pullner A, King SB, et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cell and results in spontaneous fatal autoimmunity. J Exp Med. 2009;206:549–559
  25. Von Boehmer H, Nolting J. What turns on Foxp3?. Nat Immunol. 2008;9:121–122
  26. Tone Y, Furuuchi K, Kojima Y, et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol. 2008;9:194–202
  27. Gaipl US, Beyer TD, Baumann I, et al. Exposure of anionic phospholipids serves as anti-inflammatory and immunosuppressive signal—Implications for antiphospholipid syndrome and systemic lupus erythematosus. Immunobiology. 2003;207:73–81
  28. Munoz LE, Gaipl US, Franz S, et al. SLE—A disease of clearance deficiency?. Rheumatology. 2005;44:1101–1107
  29. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005;174:7506–7515
  30. Khor B, Makar RS. Toward a molecular explanation for cross-presentation of antigens to the immune system. Transfus Med Rev. 2008;22:188–201
  31. Blachėre NE, Darnell RB, Albert ML. Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PloS Biol. 2005;3:e185
  32. Kurts C, Sutherland RM, Davey G, et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci USA. 1999;96:12703–12707
  33. Kurts C, Health WR, Kosaka H, et al. The peripheral deletion of autoreactive CD8 T cells induced by cross-presentation of self-antigens involves signaling through CD95 (Fas, Apo-1). J Exp Med. 1998;188:415–420
  34. Yamazaki S, Dudziak D, Heidkamp GF, et al. CD8+CD205+ splenic dendritic cells are specialized to induce FOXP3+ regulatory T cells. J Immunol. 2008;181:6923–6933
  35. Bird L. T cell responses: Directing responses in death. Nat Rev Immunol. 2009;9:222
  36. Torchinsky MB, Garoude J, Martin AP, Blander M. Innate immune recognition of infected apoptotic cells directs TH17 cell differentiation. Nature. 2009;458:78–82
  37. Stockinger B. Cause of death matters. Nature. 2009;458:44–45
  38. Kanai K, Watanabe M. Clinical application of human CD4+CD25+ regulatory T cells for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2005;5:451–462
  39. Lathrop SK, Santacruz NA, Pham D, et al. Antigen-specific peripheral shaping of the natural regulatory T cell population. J Exp Med. 2008;205:3105–3117
  40. Klinger M, Kim JK, Chmura SA, et al. Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J Immunol. 2009;182:4581–4589
  41. Jiang H, Chess L. Qa-1/HLA-E restricted regulatory CD8+ T cells and self-nonself discrimination: An essay on peripheral T-cell regulation. Hum Immunol. 2008;69:721–727
  42. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med. 2002;195:695–704
  43. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome(IPEX) is caused by mutations of FOXP3. Nat Genet. 2001;27:20–21
  44. Zheng Y, Chaudhry A, Kas A, et al. Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responses. Nature. 2009;458:351–356
  45. Sgouroudis E, Piccirillo CA. Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: Lessons from mouse models and implications for human disease. Diabetes Metab Res Rev. 2009;25:208–218
  46. Kuhn A, Beissert S, Krammer PH. CD4(+) CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res. 2009;301:71–81
  47. Kamikozuru K, Fukunaga K, Hirota S, et al. The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein p3+, in patients with ulcerative colitis during active and quiescent disease. Clin Exp Immunol. 2009;156:320–327
  48. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–1061
  49. Rong G, Zhou Y, Xiong Y, et al. Imbalance between T helper Type 17 and T regulatory cells in patients with primary biliary cirrhosis: The serum cytokine profile and peripheral cell population. Clin Exp Immunol. 2009;156:217–225
  50. Chen CC, Manning AM. TGF-β1, IL-10 and IL-4 differentially modulate the cytokine-induced expression of IL-6 and IL-8 in human endothelial cells. Cytokine. 1996;8:58–65
  51. Ashwood P, Harvey R, Verjee T, et al. Functional interactions between mucosal IL-1, IL-ra and TGF-beta1 in ulcerative colitis. Inflamm Res. 2004;53:53–59
  52. Gomez G, Ramirez C, Rivera J, et al. TGF-β1 inhibits mast cell FcɛR1 expression. J Immunol. 2005;174:5987–5993
  53. Brivio F, Fumagalli L, Parolini D, et al. T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients. In Vivo. 2008;22:647–650
  54. Editorial: Essence of harmony. Nat Immunol. 2005;6:325
  55. Pincus MR, Abraham NZ. Interpreting laboratory results. In:  Henry JB editors. Clinical Diagnosis and Management by Laboratory Methods. Ed 12. Philadelphia: W.B. Saunders; 2001;p. 92–107
  56. Edelson RL. Photopheresis: A new therapeutic concept. Yale J Biol Med. 1989;62:565–577
  57. Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol. 2005;174:5968–5976
  58. Legitimo A, Consolini R, Di Stefano R, et al. Psoralen and UVA light: An in vitro investigation of multiple immunological mechanisms underlying the immunosuppression induction in allograft rejection. Blood Cells Mol Dis. 2002;29:24–34
  59. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation. 2006;79:846–850
  60. Savill J, Dransfield I, Gregory C, et al. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965–975
  61. Morelli AE, Larregina AT, Shufesky WJ, et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: Dependence on complement receptors and effect on cytokine production. Blood. 2003;101:611–620
  62. Mahnke K, Knop J, Enk AH. Induction of tolerogenic DCs: “You are what you eat”. Trends Immunol. 2003;24:646–651
  63. Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191:411–416
  64. Gerner M, Hölig K, Wehner R, et al. Extracorporeal photopheresis efficiently impairs the proinflammatroy capacity of human 6-sulfo Lac NAc dendritic cells. Transplantation. 2009;87:1134–1139
  65. Maeda A, Schwarz A, Bullinger A, et al. Experimental extracorporeal photopheresis inhibits the sensitization and effector phases of contact hypersensitivity via two mechanisms: Generation of IL-10 and induction of regulatory T cells. J Immunol. 2008;181:5956–5962
  66. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood. 2008;112:1515–1521
  67. Lamioni A, Carsetti R, Legato A, et al. Induction of regulatory T cells after prophylactic treatment with photopheresis in renal transplant recipients. Transplantation. 2007;83:1393–1396
  68. Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: Clinical practice guidelines based on field experience and review of the literature. Transfusion. 2009;47:2276–2289
  69. Couriel D, Hosing C, Saliba R, et al. Extracorporeal photopheresis for acute and chronic graft-versus-host disease: Does it work?. Biol Blood Marrow Transplant. 2009;12:37–40
  70. Messina C, Locatelli F, lanino E, et al. Extracorporeal photochemotherapy for paediatric patients post stem cell transplantation. Br J Haematol. 2003;122:118–127
  71. O'Hagan AR, Stillwell PC, Arroliga A, et al. Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest. 1999;115:1459–1462
  72. Barr ML, Melser BM, Elsen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med. 1998;339:1744–1751
  73. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29:719–725
  74. Opelz G, Sengar DPS, Mickey MR, et al. Effect of blood transfusion on subsequent kidney transplants. Transplant Proc. 1973;5:253–259
  75. Landers DF, Hill GE, Wong KC, et al. Blood transfusion-induced immunomodulation. Anesth Analg. 1996;82:187–204
  76. Peters WR, Fry RD, Fleshman JW, et al. Multiple blood transfusions reduce the recurrence rate of Crohn's disease. Dis Colon Rectum. 1989;32:749–753
  77. Williams JG, Hughes LE. Effect of perioperative blood transfusion on recurrence of Crohn's disease. Lancet. 1989;2:131–133
  78. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunization with paternal cells. Lancet. 1985;1:941–943
  79. Dzik WH, Szczepiorkowski ZM. Leukocyte reduced products. In:  Hillyer CD,  Silberstein LE,  Ness PM,  Anderson KC editor. Blood Banking and Transfusion Medicine Basic Principles & Practice. 1st ed. Philadelphia: Churchill Livingstone; 2003;p. 219–220
  80. Womer KL, Sayegh MH. Donor antigen and transplant tolerance strategies: It takes two to tango!. J Am Soc Nephrol. 2004;15:1101–1103
  81. Persijn GG, Cohen B, Lansbergen Q, et al. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in the Netherlands. Transplantation. 1979;28:396–401
  82. Blajchman MA, Bardossy L, Carmen R, et al. Allogeneic blood-transfusion–induced enhancement of tumor growth: Two animal models showing amelioration by leukodepletion and passive transfer using spleen cells. Blood. 1993;81:1880–1892
  83. Bordin J, Bardossy L, Blajchman MA. Growth enhancement of established tumors by allogeneic blood transfusion in experimental animals and its amelioration by leukodepletion: The importance of timing of leukodepletion. Blood. 1994;84:344–348
  84. Thomson AW, Lu L, Murase N, et al. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells. 1995;13:622–639
  85. Clark DA, Gorczynski RM, Blajchman MA. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen. Transfusion. 2008;48:814–821
  86. Blajchman MA, Bordin JO. Mechanisms of transfusion-associated immunosuppression. Curr Opin Hematol. 1994;1:457–461
  87. Hébert PC, Fergusson D, Blajchman MA, et al. Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003;289:1941–1949
  88. Borel JF, Kis ZL. The discovery and development of cyclosporine. Transplant Proc. 1991;23:1867–1874
  89. Blajchman MA. Transfusion immunomodulation or TRIM: What does it mean clinically?. Hematology. 2005;10(Suppl 1):208–214
  90. Opelz G, Vanrenterghem Y, Kirste G, et al. prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation. 1997;63:964–967
  91. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion. 1990;30:651–658
  92. Klein L, Khazaie K, Von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci USA. 2003;100:8886–8891
  93. Waanders MM, Roelen DL, Brand A, et al. The putative mechanism of the immunomodulating effect of HLA-DR shared allogeneic blood transfusions on the alloimmune response. Transfus Med Rev. 2005;19:281–287
  94. Claas FH, de Koster HS, Lagaaij EL, et al. A molecular mechanism of T cell downregulation by blood transfusion. Exp Nephrol. 1993;1:134–138
  95. Roelen DL, van Bree S, van Hulst P, et al. Regulatory functions of human CD4(+) T cells recognizing allopeptides in the context of self-HLA class II. Hum Immunol. 2002;63:902–911
  96. Roelen D, Brand A, Claas FH. Pretransplant blood transfusions revisited: A role for CD(4+) regulatory T cells?. Transplantation. 2004;77:S26–S28
  97. Böhm M, Luger TA, Schneider M, et al. New insight into immunosuppression and treatment of autoimmune diseases. Clin Exp Rheumatol. 2006;24(suppl. 40):S67–S71
  98. Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: Role of immunosuppressive drugs. J Am Soc Nephrol. 2007;18:1007–1018
  99. Guerin LR, Prins JR, Robertson SA. Regulatory T cells and immune tolerance in pregnancy: A new target for infertility treatment?. Hum Reprod Update. 2009;15:517–535

PII: S0887-7963(09)00088-1

doi: 10.1016/j.tmrv.2009.09.008

Transfusion Medicine Reviews
Volume 24, Issue 1 , Pages 22-32 , January 2010

Article Tools

* Image Usage & Resolution